336 related articles for article (PubMed ID: 15698764)
21. Synthesis and biological activity of novel 1,2-disubstituted benzene derivatives as factor Xa inhibitors.
Koshio H; Hirayama F; Ishihara T; Shiraki R; Shigenaga T; Taniuchi Y; Sato K; Moritani Y; Iwatsuki Y; Kaku S; Katayama N; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2005 Feb; 13(4):1305-23. PubMed ID: 15670939
[TBL] [Abstract][Full Text] [Related]
22. Potential role of activated factor VIII (FVIIIa) in FVIIa/tissue factor-dependent FXa generation in initiation phase of blood coagulation.
Furukawa S; Nogami K; Ogiwara K; Shima M
Int J Hematol; 2019 Apr; 109(4):390-401. PubMed ID: 30756344
[TBL] [Abstract][Full Text] [Related]
23. Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa.
Mederski WW; Dorsch D; Anzali S; Gleitz J; Cezanne B; Tsaklakidis C
Bioorg Med Chem Lett; 2004 Jul; 14(14):3763-9. PubMed ID: 15203158
[TBL] [Abstract][Full Text] [Related]
24. The antithrombotic and anti-inflammatory effects of BCX-3607, a small molecule tissue factor/factor VIIa inhibitor.
Arnold CS; Parker C; Upshaw R; Prydz H; Chand P; Kotian P; Bantia S; Babu YS
Thromb Res; 2006; 117(3):343-9. PubMed ID: 16378835
[TBL] [Abstract][Full Text] [Related]
25. Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model.
Lefkovits J; Malycky JL; Rao JS; Hart CE; Plow EF; Topol EJ; Nicolini FA
J Am Coll Cardiol; 1996 Dec; 28(7):1858-65. PubMed ID: 8962577
[TBL] [Abstract][Full Text] [Related]
26. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.
Maduskuie TP; McNamara KJ; Ru Y; Knabb RM; Stouten PF
J Med Chem; 1998 Jan; 41(1):53-62. PubMed ID: 9438022
[TBL] [Abstract][Full Text] [Related]
27. Activity of secreted Kunitz domain 1 variants of tissue factor pathway inhibitor.
Johnson K; Zaror I; Bauer D; Choi Y; Creasey A; Innis M
Thromb Haemost; 1998 Oct; 80(4):585-7. PubMed ID: 9798974
[TBL] [Abstract][Full Text] [Related]
28. Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation.
Kjalke M; Monroe DM; Hoffman M; Oliver JA; Ezban M; Roberts HR
Thromb Haemost; 1998 Oct; 80(4):578-84. PubMed ID: 9798973
[TBL] [Abstract][Full Text] [Related]
29. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor.
Hackeng TM; Seré KM; Tans G; Rosing J
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3106-11. PubMed ID: 16488980
[TBL] [Abstract][Full Text] [Related]
30. Probing the interface between factor Xa and tissue factor in the quaternary complex tissue factor-factor VIIa-factor Xa-tissue factor pathway inhibitor.
Carlsson K; Freskgård PO; Persson E; Carlsson U; Svensson M
Eur J Biochem; 2003 Jun; 270(12):2576-82. PubMed ID: 12787023
[TBL] [Abstract][Full Text] [Related]
31. Peptide exosite inhibitors of factor VIIa as anticoagulants.
Dennis MS; Eigenbrot C; Skelton NJ; Ultsch MH; Santell L; Dwyer MA; O'Connell MP; Lazarus RA
Nature; 2000 Mar; 404(6777):465-70. PubMed ID: 10761907
[TBL] [Abstract][Full Text] [Related]
32. Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors.
Groebke Zbinden K; Banner DW; Ackermann J; D'Arcy A; Kirchhofer D; Ji YH; Tschopp TB; Wallbaum S; Weber L
Bioorg Med Chem Lett; 2005 Feb; 15(3):817-22. PubMed ID: 15664864
[TBL] [Abstract][Full Text] [Related]
33. [Tissue factor pathway inhibitors].
Sierko E; Zawadzki RJ; Wojtukiewicz MZ
Pol Merkur Lekarski; 2002 Jul; 13(73):66-9. PubMed ID: 12362512
[TBL] [Abstract][Full Text] [Related]
34. Rational design, synthesis, and structure-activity relationships of novel factor Xa inhibitors: (2-substituted-4-amidinophenyl)pyruvic and -propionic acids.
Sagi K; Nakagawa T; Yamanashi M; Makino S; Takahashi M; Takayanagi M; Takenaka K; Suzuki N; Oono S; Kataoka N; Ishikawa K; Shima S; Fukuda Y; Kayahara T; Takehana S; Shima Y; Tashiro K; Yamamoto H; Yoshimoto R; Iwata S; Tsuji T; Sakurai K; Shoji M
J Med Chem; 2003 May; 46(10):1845-57. PubMed ID: 12723948
[TBL] [Abstract][Full Text] [Related]
35. An all-atom solution-equilibrated model for human extrinsic blood coagulation complex (sTF-VIIa-Xa): a protein-protein docking and molecular dynamics refinement study.
Venkateswarlu D; Duke RE; Perera L; Darden TA; Pedersen LG
J Thromb Haemost; 2003 Dec; 1(12):2577-88. PubMed ID: 14750502
[TBL] [Abstract][Full Text] [Related]
36. The discovery of fluoropyridine-based inhibitors of the factor VIIa/TF complex--Part 2.
Kohrt JT; Filipski KJ; Cody WL; Cai C; Dudley DA; Van Huis CA; Willardsen JA; Narasimhan LS; Zhang E; Rapundalo ST; Saiya-Cork K; Leadley RJ; Edmunds JJ
Bioorg Med Chem Lett; 2006 Feb; 16(4):1060-4. PubMed ID: 16289811
[TBL] [Abstract][Full Text] [Related]
37. Factor VIIa inhibitors: chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model.
Young WB; Mordenti J; Torkelson S; Shrader WD; Kolesnikov A; Rai R; Liu L; Hu H; Leahy EM; Green MJ; Sprengeler PA; Katz BA; Yu C; Janc JW; Elrod KC; Marzec UM; Hanson SR
Bioorg Med Chem Lett; 2006 Apr; 16(7):2037-41. PubMed ID: 16412633
[TBL] [Abstract][Full Text] [Related]
38. Potent and selective TF/FVIIa inhibitors containing a neutral P1 ligand.
Miura M; Seki N; Koike T; Ishihara T; Niimi T; Hirayama F; Shigenaga T; Sakai-Moritani Y; Kawasaki T; Sakamoto S; Okada M; Ohta M; Tsukamoto S
Bioorg Med Chem; 2006 Dec; 14(23):7688-705. PubMed ID: 16942884
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in serine protease inhibitors as anticoagulant agents.
Prezelj A; Anderluh PS; Peternel L; Urleb U
Curr Pharm Des; 2007; 13(3):287-312. PubMed ID: 17313362
[TBL] [Abstract][Full Text] [Related]
40. Inhibitors of factor VIIa affect the interface between the protease domain and tissue factor.
Carlsson K; Persson E; Carlsson U; Svensson M
Biochem Biophys Res Commun; 2006 Oct; 349(3):1111-6. PubMed ID: 16970919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
